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Disease activity scoreAbstract Background: Rheumatoid arthritis (RA) is a systemic, chronic inﬂammatory disease
with genetic predisposition. Osteopontin (OPN) is overexpressed in RA and plays a key role in
the perpetuation of synovitis. Not all RA patients show the same level of response to methotrexate
(MTX) suggesting genetic variations in the drug-metabolizing enzymes.
Aim of the work: To detect methylene-tetra-hydrofolate reductase (MTHFR) 677C/T and
1298A/C gene polymorphisms in RA patients treated with MTX and to investigate the relationship
with serum OPN levels and disease activity.
Patients and methods: 62 RA patients and 21 healthy controls were included. Serum OPN was
measured using ELISA. Genotyping of MTHFR gene was carried out by polymerase chain
reaction-restriction fragment length polymorphism. Disease activity score in 28 joints (DAS28)
and the modiﬁed health assessment questionnaire (MHAQ) were assessed.
Results: The patients’ age was 42.7 ± 12.7 years, F:M (4.6:1) and a disease duration of 5.7
± 4.6 years. Their DAS28 was 4.1 ± 1.6 and the MHAQ (median 1; range 0–2.3). Serum OPN
levels in RA patients (median 8.8; range 4–44.5 ng/ml) were signiﬁcantly higher than in control
(5.6; 2.1–10.9) (p= 0.002). In RA patients, serum OPN signiﬁcantly correlated with the duration
of morning stiffness (p= 0.009), ESR (p< 0.0001) and DAS28 (p< 0.0001). MTHFR
(677C>T) polymorphisms signiﬁcantly correlated with MHAQ (p= 0.012) while (1298A>C)
polymorphisms signiﬁcantly correlated with tender joint count (p= 0.04). OPN levels were higher
among patients with MTHFR (1298A/C) AC genotype (8.9; 4.1–33.9 ng/ml), while in those with
(677C>T) polymorphisms it was higher among those with CT genotype (8.9; 4.1–44.5).Haram,
284 O.G. Shaker et al.Conclusion: Serum OPN level relates with the degree of rheumatoid activity.
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Rheumatoid arthritis (RA) is a chronic progressive inﬂamma-
tory disease, characterized by synovial inﬂammation and
hyperplasia leading to progressive cartilage and bone destruc-
tion [1]. Many factors have been implicated in the pathogenesis
of Egyptian RA patients as tumor necrosis factor-a (TNF-a)
and IL-6 with their gene polymorphisms [2,3], interleukin-17
(IL-17) and T helper lymphocytes [4], metalloproteinases
(MMPs) [5], angiopoitin-2 [6], osteoprotegerin and RANKL
[7] as well as CD14++CD16+ monocyte subpopulation [8].
Although the pathogenesis of RA remains unknown and the
molecular mechanisms involved are poorly understood, there
is evidence suggesting that T cell-mediated inﬂammation plays
an important role [9].
Osteopontin (OPN), also known as early T lymphocyte
activation-1, is an extracellular matrix protein with pleiotropic
functions, including a proinﬂammatory function [10]. It has
been recognized as a potential biomarker in multiple sclerosis
and osteoporosis [11], osteoarthritis [12,13], systemic lupus
erythematosus (SLE) [14], psoriasis [15], inﬂammatory bowel
disease (IBD) [16] as well as in RA [17–19]. It is classiﬁed as
a Th1 cytokine because of its ability to enhance the production
of interferon-c (IFN-c) and IL-12 in macrophages [9]. OPN
has been involved in joint destruction and arthritis and a direct
role in bone re-adsorption beyond its effects on inﬂammation
has been suggested [20]. OPN overexpression in RA synovium
was attributable, at least in part, to IL-10 which has been
found to correlate with autoantibody production and B cell
activation in RA and to contribute to the disease process
[21]. OPN also regulates genes related to nuclear factor-jB
(NF-jB) transcription pathway and TNF receptor family
known to play a critical role in the production of many inﬂam-
matory mediators [22,23].
The principal pharmacological effect of methotrexate
(MTX) is through folate antagonism. MTX enters the cell
through reduced folate carrier-1 and is intracellularly polyglu-
tamated. Polyglutamation enhances the intracellular retention
of MTX and promotes inhibition of de novo purine synthesis
along with the buildup of adenosine, a potent anti-
inﬂammatory agent [24]. MTX inhibits folate pathway
enzymes directly as dihydrofolate reductase and indirectly as
methylene-tetra-hydrofolate reductase (MTHFR) [25]. Gene
polymorphisms related to MTX cell membrane transport
and the enzymes involved in their cellular metabolic pathway
have been described; with particular note are two MTHFR
SNPs 677C/T and 1298A/C [24].
Based on these literature reports, the aim of the present
study was to investigate MTHFR gene polymorphisms in
RA patients treated with MTX and the possible relationship
with plasma OPN levels and disease activity.2. Patients and methods
Sixty-two RA patients diagnosed according to the 2010 ACR/
EULAR RA classiﬁcation criteria [26] were consecutively
recruited from the outpatient clinic of Internal medicine
department, Beni-Sweif University. They were 51 females, 11
males with a mean age of 42.7 ± 12.7 years and disease dura-
tion of 5.7 ± 4.6 years. 21 age (52.7 ± 6.5 years) and gender
(15 females, 6 males) matched healthy volunteers served as
controls. The study was approved by the Local Research
Ethics Committee of Beni-Sweif University and conforms to
the provisions of the Declaration of Helsinki in 1995. All
patients gave their informed consent prior to their inclusion
in the study.
All patients had complete medical workup including full
history taking and complete physical examination. Assessment
included number of tender (TJC) and swollen joint count
(SJC), disease activity score in 28 joints (DAS-28) [27] and
modiﬁed health assessment questionnaire (MHAQ) score
[28]. Blood samples were collected for estimation of the ery-
throcyte sedimentation rate (ESR), C-reactive protein (CRP)
and complete blood count (CBC).
2.1. Quantitation of serum osteopontin
This was done by ELISA kit provided by quantikine, R&D
systems, UK. This assay employs the quantitative sandwich
enzyme immunoassay technique. A monoclonal antibody
speciﬁc for OPN has been pre-coated onto a microplate. Stan-
dards and samples are pipetted into the wells and any OPN
present is bound by the immobilized antibody. After washing
away any unbound substances, an enzyme-linked polyclonal
antibody speciﬁc for OPN is added to the wells. Following a
wash to remove any unbound antibody-enzyme reagent, a sub-
strate solution is added to the wells and color develops in pro-
portion to the amount of OPN bound in the initial step. The
color development is stopped and its intensity measured.
2.2. Genotyping of the MTHFR 677C>T and 1298A>C
Genomic DNA was extracted from peripheral blood using a
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s protocol. Genotyping
was performed by polymerase chain reaction-restriction frag-
ment length polymorphism (PCR–RFLP).
Genotyping of MTHFR 677C>T: speciﬁc primers ‘‘50-CAT
CCC TAT TGG CAG GTT AC-30” and ‘‘50-GAC GGT GCG
GTG AGA GTG-30” were used for ampliﬁcation of a frag-
ment of 265 base pairs. PCR products were digested with HinfI
enzyme. PCR proﬁle was: initial denaturation at 94 C for
Table 1 Demographic features, serum osteopontin and
MTHFR genotype distribution in RA patients and control as
well as clinical characteristics of the patients.
Variable RA patients (n= 62) Controls (n= 21)
Age (years) 42.7 ± 12.7 52.7 ± 6.5
Sex F:M 4.6:1 2.5:1
Disease duration (years) 5.7 ± 4.6 –
Morning stiﬀness (min) 32.5 ± 39.2 –
TJC 4 (0–20) –
SJC 1 (0–18) –
DAS28 4.1 ± 1.6 –
MHAQ 1 (0–2.3) –
ESR (mm/h) 20 (5–125) –
Osteopontin (ng/ml) 8.8 (4–44.5) 5.6 (2.1–10.9)
MTHFR polymorphism
(677C>T) CC 26 (41.9) 15 (71.4)
CT 30 (48.4) 5 (23.8)
TT 6 (9.7) 1 (4.8)
(1298A>C) AA 26 (41.9) 5 (23.8)
AC 22 (35.5) 13 (61.9)
CC 14 (22.6) 3 (14.3)
RA: rheumatoid arthritis, TJC: tender joint count, SJC: swollen
joint count, DAS28: disease activity score in 28 joints, MHAQ:
modiﬁed health assessment questionnaire, ESR: erythrocyte sedi-
mentation rate, MTHFR: methylene-tetra-hydrofolate reductase.
Values are presented as mean ± SD, median (range) or n (%).
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annealing at 59 C for 30 s, extension at 72 C for 30 s, fol-
lowed by 10 min at 72 C. In 677 of MTHFR gene, change
of C>T, produces a cut site for HinfI enzyme, which produces
two fragments of 171 and 94 bp. Then, CC genotype gives sin-
gle band of 265 bp (uncut), CT genotype by three bands of
265, 171 and 94 bp, and TT genotypes by two bands of 171
and 94 bp.
Genotyping of MTHFR 677C>T: a set of forward ‘‘50-CTT
TGG GGA GCT GAA GGA CTA CTA C-3” and reverse
‘‘50-CAC TTT GTG ACC ATT CCG GTT TG-3” primers
were used for ampliﬁcation of a fragment of 241 base pairs
and then the ampliﬁed fragment was digested with MboII
enzyme. The PCR proﬁle was: initial denaturation at 95 C
for 5 min, denaturation at 94 C for 30 s, annealing at 51 C
for 30 s, extension at 72 C for 30 s for 35 cycles and followed
at 72 C for 10 min. In the position 1298 of MTHFR gene,
transversion of ‘‘A” to ‘‘C” produces a cut site for MboII
enzyme, which cuts the amplicons into two fragments of 211
and 30 bp. Then, AA genotype results in a single band of
241 bp (uncut), AC genotypes produce three bands of 241,
211 and 30 bp, and CC genotype produces two bands of 211
and 30 bp. Digestion of 10 ll PCR products was carried out
with 1.5 U HinfI and MboII restriction enzyme in 37 C for
two hours for MTHFR 677CT and 1298AC genotyping,
respectively. Then, products were electrophoresed on 3% agar-
ose gel. Gel was stained with ethidium bromide and presence
or absence of products was observed by UV transilluminator.
2.3. Statistical analysis
Data were collected, tabulated and statistically analyzed using
SPSS (statistical program for social science) version 16 win-
dows. Quantitative variables were described as mean, SD,
median and range and qualitative variables as n (number)
and %. Chi-square test was used to compare qualitative vari-
ables and unpaired t-test was used to compare two indepen-
dent groups as regards quantitative variables. Correlation
between parameters was performed using Pearson correlation
coefﬁcient. Strength of association between RA and alleles
or genotypes of the MTHFR gene polymorphism was esti-
mated using odds ratios (ORs) and 95% conﬁdence intervals
(CIs). Levels of signiﬁcance were determined using contin-
gency tables by chi-square analysis. Strength of association
between osteopontin levels in RA and alleles or genotypes of
polymorphisms in the MTHFR gene was estimated using the
OR and 95% CI. The data were considered signiﬁcant if p
value was 60.05 and highly signiﬁcant if p< 0.01.
3. Results
Sixty-two RA patients with a mean age of 42.7 ± 12.7 years
(F:M 4.6:1) and disease duration of 5.7 ± 4.6 years were
included as well as 21 age and gender matched control. Demo-
graphic features, plasma osteopontin level and MTHFR gene
polymorphisms for the patients and control as well as the
patients’ clinical characteristics are shown in Table 1.
Demographic, clinical and laboratory characteristics of RA
patients according to their MTHFR gene polymorphism are
presented in Tables 2 and 3. RA patients with MTHFR
1298AC and 677CT genotypes showed higher serum OPNlevels. However, the difference was not statistically signiﬁcant.
The signiﬁcance of difference in osteopontin levels among the
studied genotypes is shown in Table 4. The signiﬁcance of dif-
ference in the genotypic frequencies between RA patients and
controls is presented in Table 5.
Serum OPN levels were signiﬁcantly higher in RA patients
(median: 8.8, range 4–44.5 ng/ml) as compared to healthy con-
trols (median: 5.56, range 2.05–10.85 ng/ml) (p= 0.002).
In RA patients, serum osteopontin levels showed a signiﬁ-
cant correlation with the duration of morning stiffness
(r= 0.33, p= 0.009), ESR (r= 0.86, p< 0.0001), DAS 28
(r= 0.55, p< 0.0001) and negative correlation with hemoglo-
bin levels (r= 0.47, p< 0.0001). However serum OPN levels
showed a non signiﬁcant correlation with age, disease dura-
tion, TJC, SJC, platelet count and MHAQ.
There was a signiﬁcant correlation between MTHFR
(677C>T) gene polymorphisms and MHAQ (p= 0.012) while
a non-signiﬁcant correlation was found with the disease dura-
tion (p= 0.22); duration of morning stiffness (p= 0.63); TJC
(p= 0.44); SJC (p= 0.48); DAS28 (p= 0.14); ESR
(p= 0.22) and serum osteopontin levels (p= 0.42).
A signiﬁcant correlation was found between MTHFR
(1298A>C)gene polymorphisms and theTJC (p= 0.04).How-
ever a non-signiﬁcant correlation was found with the disease
duration (p= 0.3); duration of morning stiffness (p= 0.79);
SJC (p= 0.35); DAS28 (p= 0.42); MHAQ (p= 0.77); ESR
(p= 0.42) and serum osteopontin levels (p= 0.95).
4. Discussion
The MTHFR enzyme is very important in the regeneration of
reduced folate. The MTHFR C677T polymorphism results in a
thermolabile variant with decreased enzyme activity [29]. A
Table 3 Demographic, clinical and laboratory characteristics of RA patients according to their MTHFR (677C>T) gene
polymorphism.
Mean ± SD or median (range) MTHFR (677C>T) in RA patients (n= 62)
TT (n= 6) CT (n= 30) CC (n= 26)
Age (years) 43.7 ± 18.2 41.5 ± 12.6 43.8 ± 11.9
Disease duration (years) 8 ± 3.9 5.9 ± 4.8 5.04 ± 4.3
Morning stiﬀness (min) 16 ± 12.1 36 ± 40.6 32.3 ± 41.7
TJC 4 (0–5) 4 (0–20) 2 (0–13)
SJC 0 (0–3) 1 (0–18) 1 (0–14)
DAS28 3.7 ± 0.97 4.4 ± 1.5 3.7 ± 1.8
MHAQ 1.1 (0.9–1.6) 0.8 (0–1.8) 1 (0–2.3)
ESR (mm/h) 20 (19–50) 20 (7–125) 14 (5–81)
Osteopontin (ng/ml) 8.8 (5.4–21) 8.9 (4.1–44.5) 6.3 (4–22.4)
MTHFR: methylene-tetra-hydrofolate reductase, RA: rheumatoid arthritis, TJC: tender joint count, SJC: swollen joint count, DAS28: disease
activity score in 28 joints, MHAQ: modiﬁed health assessment questionnaire, ESR: erythrocyte sedimentation rate.
Table 2 Demographic, clinical and laboratory characteristics of RA patients according to their MTHFR (1298A>C) gene
polymorphism.
Mean ± SD or median (range) MTHFR (1298A>C) in RA patients (n= 62)
AA (n= 26) AC (n= 22) CC (n= 14)
Age (years) 42.2 ± 12.5 45.7 ± 12.8 38.7 ± 12.6
Disease duration (years) 5.04 ± 4.4 5.7 ± 5.2 7 ± 3.8
Morning stiﬀness (min) 39.2 ± 48.1 34.6 ± 38.1 16.9 ± 8.3
TJC 4 (0–20) 5 (0–20) 2 (0–5)
SJC 1 (0–15) 1 (0–18) 0 (0–3)
DAS28 4.1 ± 1.9 4.44 ± 1.6 3.5 ± 0.1
MHAQ 1 (0–2.3) 1 (0–1.8) 1 (0.1–1.9)
ESR (mm/h) 14 (5–110) 20 (7–125) 20 (12–9)
Osteopontin (ng/ml) 6.3 (4–44.5) 8.9 (4.1–33.9) 8.8 (4.5–32.4)
MTHFR: methylene-tetra-hydrofolate reductase, RA: rheumatoid arthritis, TJC: tender joint count, SJC: swollen joint count, DAS28: disease
activity score in 28 joints, MHAQ: modiﬁed health assessment questionnaire, ESR: erythrocyte sedimentation rate.
Table 5 Comparison of the genotypic frequencies between
RA patients and controls.
MTHFR alleles Frequency
(patients:controls)
OR (95%
CI)
p
(677C>T) TT/
CC
18.8/6.3:81.3/93.8 3.4 (0.4–
31.6)
0.24
CT/
CC
53.6/25: 46.4/75 3.4 (1.1–
10.8)
0.02
(1298A>C) AA/
CC
65/62.5: 35/37.5 1.11 (0.2–
5.4)
0.89
AC/
CC
61.1/81.3:38.9/18.8 0.36 (0.1–
1.5)
0.15
MTHFR: methylene-tetra-hydrofolate reductase. Bold value is
signiﬁcant at p< 0.05.
Table 4 Signiﬁcance of difference in osteopontin levels among
the studied genotypes.
MTHFR gene Genotype Osteopontin (median) p
(677C>T) TT/CT 8.8/8.9 0.9
TT/CC 8.8/6.3 0.5
CT/CC 8.9/6.3 0.2
(1298A>C) AA/AC 6.3/8.9 0.71
AA/CC 6.3/8.8 0.95
AC/CC 8.9/8.8 1
286 O.G. Shaker et al.wide range of side effects are associated with this polymor-
phism as gastrointestinal [30], hepatic toxicity [31], overall
adverse events [32] and a less likely response to MTX [24],
however, other authors have not found any effects on toxicity
and efﬁcacy [33,34]. The A1298C polymorphism also results in
decreased MTHFR activity and exhibits other discrepancies in
its clinical effects. Some studies of carriers of this allele suggest
increased MTX efﬁcacy [31,32], increased susceptibility to RA
[33] and increased risk of toxicity [24,35,36] however, another
study did not ﬁnd any effects on efﬁcacy and toxicity [34].
In RA, it is highly appropriate to start directly with ade-
quate therapy to reduce joint damage, radiographic progres-sion and functional decline. The importance of early and
sustained suppression of disease activity in RA has been shown
[14,15]. MTX is the most widely used disease-modifying anti-
rheumatic drug (DMARD) for the treatment of RA, and has
proven to reduce disease activity and delay or stabilize the
development of bone erosions [37]. However, not all patients
show the same level of response to MTX. These variations
Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in RA patients 287suggest that RA patients may have genetic variations in drug-
metabolizing enzymes. Associations of polymorphisms in the
gene coding for MTHFR with MTX efﬁcacy and toxicity have
been reported. In this context, pharmacogenetic studies may
offer a novel strategy to identify predictors of response to
MTX treatment [18,19,38].
Owing to the implication of OPN in ampliﬁcation and per-
petuation of inﬂammation in the rheumatoid synovium, the
aim of the current study was to investigate the possible associ-
ation between MTHFR gene polymorphisms and serum OPN
levels to determine the relationship between polymorphisms in
the gene coding for MTHFR with MTX efﬁcacy in RA
patients. In the present study, serum OPN levels were signiﬁ-
cantly higher in RA patients compared to controls
(p= 0.002). This was supported by the ﬁndings of Bazzichi
and colleagues [37] suggesting a peculiar role for this protein
in RA pathogenesis. Xu and coworkers [22] revealed that
mRNA expression of OPN was highly elevated in CD4+ syn-
ovial T cells derived from RA patients which correlated with
increased OPN concentrations in synovial ﬂuid.
In our study, serum OPN levels showed a signiﬁcant corre-
lation with the duration of morning stiffness, ESR and DAS 28
in RA patients. This was in agreement with another study [39]
which showed a signiﬁcantly higher OPN levels in RA patients
than in healthy controls and were correlated with the CRP
levels. Furthermore, Shio and colleagues [40] reported that
OPN was signiﬁcantly higher in RA patients than in healthy
controls or OA patients and correlated signiﬁcantly with
CRP and ESR as markers of disease activity. However, Ji
and colleagues [41] showed that serum OPN level in RA
patients was not signiﬁcantly correlated with the DAS28 level
or responsiveness of RA patients to therapeutic treatments.
Serum OPN level in both responders and non-responders after
therapy was signiﬁcantly decreased regardless of responsive-
ness to therapy.
In the current study, serum OPN levels tended to be higher
in RA patients with MTHFR 1298AC and 677CT genotypes.
This may be explained by the association between MTHFR
1298AC and 677CT genotypes and poor response to MTX.
It has been suggested that there are genotype differences in
MTX response with increased dosage and longer treatment
duration. For instance, patients with MTHFR 1298AA show
a higher percentage of good clinical improvement at 6 months
when compared with C allele carriers. In contrast, patients
with the MTHFR 1298AC genotype do not seem to improve
much with increased dosage or with a longer treatment period,
whereas for MTHFR 677CT, data suggest that T allele carriers
show relatively less clinical improvement upon increased MTX
dosage [42]. Dervieux and colleagues [24] reported that the
MTHFR C677CT polymorphism results in a decreased
enzyme activity and carriers of the MTHFR 677TT genotype
are less likely to respond to MTX than those with alternate
genotypes. Rego-Perez and coworkers [43] reported that
the A1298C polymorphism also results in decreased MTHFR
activity and exhibits other discrepancies in its clinical effects.
5. Conclusion
The response to therapy is probably partially determined by
the genetic makeup of the individual. This study shows that
SNPs in MTHFR gene may predict the response to MTXtreatment. These observations indicate that ascertainment of
MTHFR genotype could be useful in establishing the initial
MTX dosage to more rapidly reduce disease activity in
patients with early RA.
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